Published in Ophthalmology on June 25, 2011
Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye (Lond) (2012) 2.52
Endophthalmitis. Clin Microbiol Infect (2013) 1.79
Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) (2013) 1.67
Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis. Ophthalmic Epidemiol (2016) 1.39
Drug-induced uveitis. J Ophthalmic Inflamm Infect (2013) 1.11
The relationship of cataract and cataract extraction to age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology (2012) 1.06
Factors affecting visual outcome of myopic choroidal neovascularization treated with verteporfin photodynamic therapy. Int J Ophthalmol (2013) 1.00
Endophthalmitis: state of the art. Clin Ophthalmol (2015) 0.98
Suprachoroidal delivery in a rabbit ex vivo eye model: influence of drug properties, regional differences in delivery, and comparison with intravitreal and intracameral routes. Mol Vis (2013) 0.91
Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy. Mediators Inflamm (2013) 0.89
The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review. BMJ Open (2014) 0.89
Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask. Graefes Arch Clin Exp Ophthalmol (2013) 0.86
An anti-angiogenic reverse thermal gel as a drug-delivery system for age-related wet macular degeneration. Macromol Biosci (2013) 0.83
Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review. Int J Retina Vitreous (2015) 0.82
Identification of torque teno virus in culture-negative endophthalmitis by representational deep DNA sequencing. Ophthalmology (2014) 0.82
Effects of moxifloxacin exposure on the conjunctival flora and antibiotic resistance profile following repeated intravitreal injections. Int J Ophthalmol (2014) 0.82
Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide. Int J Pharm (2012) 0.81
The effect of prophylactic topical antibiotics on bacterial resistance patterns in endophthalmitis following intravitreal injection. Graefes Arch Clin Exp Ophthalmol (2015) 0.80
Comparative safety and tolerability of anti-VEGF therapy in age-related macular degeneration. Drug Saf (2015) 0.80
The results of pars plana vitrectomy and silicone oil tamponade for endophthalmitis after intravitreal injections. Int Ophthalmol (2013) 0.79
Emerging techniques for pathogen discovery in endophthalmitis. Curr Opin Ophthalmol (2015) 0.79
Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms. J Ophthalmic Inflamm Infect (2016) 0.76
Pigmented-MDCK (P-MDCK) cell line with tunable melanin expression: an in vitro model for the outer blood-retinal barrier. Mol Pharm (2012) 0.76
Predictive factors for recurrence of macular edema after successful intravitreal bevacizumab therapy in branch retinal vein occlusion. Jpn J Ophthalmol (2015) 0.75
Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia. Middle East Afr J Ophthalmol (2016) 0.75
Incidence of Endophthalmitis after Intravitreal Bevacizumab using Aliquots Prepared On-site in 2 Operating Rooms in Kuwait. Middle East Afr J Ophthalmol (2016) 0.75
Nanostructured materials for ocular delivery: nanodesign for enhanced bioadhesion, transepithelial permeability and sustained delivery. Ther Deliv (2015) 0.75
Clinical outcomes and antibiotic susceptibilities of Staphylococcus aureus endophthalmitis. Graefes Arch Clin Exp Ophthalmol (2016) 0.75
Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med (2012) 8.83
Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol (2003) 4.78
Incidence of endophthalmitis after 20- and 25-gauge vitrectomy. Ophthalmology (2007) 2.99
Comparison of retrobulbar and sub-Tenon's capsule injection of local anesthetic in vitreoretinal surgery. Ophthalmology (2005) 2.79
A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology (2010) 2.67
Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther (2008) 2.59
Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol (2007) 2.53
Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol (2006) 2.50
Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis. Retina (2013) 2.49
Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol (2012) 2.30
Short-term outcomes of 25-gauge vitrectomy with silicone oil for repair of complicated retinal detachment. Retina (2008) 2.28
Bimanual assisted eyelid retraction technique for intravitreal injections. Retina (2013) 2.20
Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. Ophthalmology (2004) 2.19
A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome. Ophthalmology (2002) 2.16
Serous macular detachment in Waldenström macroglobulinemia: a report of four cases. Am J Ophthalmol (2012) 2.07
Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology (2010) 2.02
Retinal thickness analysis by race, gender, and age using Stratus OCT. Am J Ophthalmol (2009) 1.86
A placebo-controlled trial of microplasmin intravitreous injection to facilitate posterior vitreous detachment before vitrectomy. Ophthalmology (2010) 1.84
Coats' disease diagnosed in adulthood. Ophthalmology (2005) 1.84
Health care economic analyses and value-based medicine. Surv Ophthalmol (2003) 1.83
Optical coherence tomography findings in acute retinal pigment epitheliitis. Am J Ophthalmol (2006) 1.80
Incremental cost-effectiveness of initial cataract surgery. Ophthalmology (2002) 1.72
A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology (2007) 1.70
The dexamethasone drug delivery system: indications and evidence. Adv Ther (2011) 1.67
Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol (2009) 1.64
Complications of intravitreal injections. Curr Opin Ophthalmol (2010) 1.63
Delayed intraocular foreign body removal without endophthalmitis during Operations Iraqi Freedom and Enduring Freedom. Ophthalmology (2007) 1.62
Correlation of visual acuity and macular thickness measured by optical coherence tomography in patients with persistent macular edema. Retina (2010) 1.56
Single-field fundus photography for diabetic retinopathy screening: a report by the American Academy of Ophthalmology. Ophthalmology (2004) 1.50
Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology (2012) 1.48
Atypical retinitis pigmentosa masquerading as primary open angle glaucoma. J Glaucoma (2007) 1.48
Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology (2008) 1.47
Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology (2005) 1.47
Intraoperative ketorolac and eye pain after viteoretinal surgery: a prospective, randomized, placebo-controlled study. Retina (2003) 1.46
Persistent diabetic macular edema is associated with elevated hemoglobin A1c. Am J Ophthalmol (2005) 1.43
Cost-utility analysis of cataract surgery in the second eye. Ophthalmology (2003) 1.41
Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging (2005) 1.38
Comparison between retinal thickness analyzer and optical coherence tomography for assessment of foveal thickness in eyes with macular disease. Am J Ophthalmol (2002) 1.36
Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology (2012) 1.32
Small-gauge pars plana vitrectomy: a report by the American Academy of Ophthalmology. Ophthalmology (2010) 1.32
Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol (2002) 1.31
Quality of life associated with visual loss: a time tradeoff utility analysis comparison with medical health states. Ophthalmology (2003) 1.31
Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. Am J Ophthalmol (2011) 1.28
Regression of a subfoveal choroidal metastasis of colorectal carcinoma after intravitreous bevacizumab treatment. Arch Ophthalmol (2008) 1.27
Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. Am J Ophthalmol (2004) 1.26
A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 2. Refractive outcome. Ophthalmology (2002) 1.26
Retinal pigment epithelial tear after intravitreal bevacizumab injection. Am J Ophthalmol (2006) 1.26
Combined phacoemulsification, intraocular lens implantation, and vitrectomy for eyes with coexisting cataract and vitreoretinal pathology. Am J Ophthalmol (2003) 1.26
Outcomes of anti-vascular endothelial growth factor therapy in the management of choroidal neovascularization associated with choroidal osteoma. Retina (2014) 1.25
A cost-utility analysis of therapy for amblyopia. Ophthalmology (2002) 1.23
Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology. Ophthalmology (2012) 1.23
Age-related macular degeneration: economic burden and value-based medicine analysis. Can J Ophthalmol (2005) 1.22
The burden of age-related macular degeneration: a value-based analysis. Curr Opin Ophthalmol (2006) 1.21
Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther (2007) 1.20
Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration. Retina (2012) 1.19
Update on treatment of retinal arterial occlusions. Curr Opin Ophthalmol (2003) 1.18
Pars plana vitrectomy versus combined pars plana vitrectomy-scleral buckle for primary repair of pseudophakic retinal detachment. Ophthalmology (2006) 1.17
Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina (2014) 1.15
Postoperative complications associated with 25-gauge pars plana vitrectomy. Ophthalmic Surg Lasers Imaging (2007) 1.15
Drug-induced uveitis. J Ophthalmic Inflamm Infect (2013) 1.11
The quality of life associated with presbyopia. Am J Ophthalmol (2008) 1.10
Intravitreal bevacizumab (avastin) in central retinal vein occlusion. Retina (2007) 1.10
Retinopathy of prematurity: the life of a lifetime disease. Am J Ophthalmol (2006) 1.08
The cost utility of strabismus surgery in adults. J AAPOS (2006) 1.04
Revised indications for early treatment of retinopathy of prematurity. Arch Ophthalmol (2005) 1.04
Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: diabetic retinopathy clinical research network. Retina (2010) 1.04
Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion. Retina (2014) 1.04
Resolution of epithelial ingrowth in a patient treated with 5-fluorouracil. Am J Ophthalmol (2002) 1.02
Spontaneous resolution of macular microhole. Am J Ophthalmol (2006) 0.99
A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema. Ophthalmology (2011) 0.98
Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration. Retina (2007) 0.98
Update on the ocular manifestations of systemic arterial hypertension. Curr Opin Ophthalmol (2004) 0.97
Impact of optical coherence tomography on surgical decision making for epiretinal membranes and vitreomacular traction. Retina (2007) 0.96
23-Gauge transconjunctival pars plana vitrectomy for removal of retained lens fragments. Am J Ophthalmol (2011) 0.95
Intravitreous dexamethasone effects on different patterns of diabetic macular edema. Arch Ophthalmol (2010) 0.95
Quality of life and systemic comorbidities in patients with ophthalmic disease. Br J Ophthalmol (2002) 0.94
Endophthalmitis after open globe injury: microbiologic spectrum and susceptibilities of isolates. Am J Ophthalmol (2006) 0.94
Abraxane-induced cystoid macular edema refractory to concomitant intravenous bevacizumab. Can J Ophthalmol (2011) 0.94
Drug-induced uveitis. Curr Opin Ophthalmol (2013) 0.94
Laser treatment for retinopathy of prematurity: evolution in treatment technique over 15 years. Retina (2006) 0.94
Hypotony after 25-gauge vitrectomy using oblique versus direct cannula insertions in fluid-filled eyes. Retina (2008) 0.93
Retinal pigment epithelial abnormalities after internal limiting membrane peeling guided by indocyanine green staining. Retina (2004) 0.93
Update on nonsurgical therapy for diabetic macular edema. Curr Opin Ophthalmol (2011) 0.92
How to interpret a healthcare economic analysis. Curr Opin Ophthalmol (2005) 0.92
Patient, community and clinician perceptions of the quality of life associated with diabetes mellitus. Med Sci Monit (2002) 0.92
Postoperative vitreous hemorrhage after diabetic 23-gauge pars plana vitrectomy. Am J Ophthalmol (2013) 0.92
Incidence of intraocular pressure spike and other adverse events after vitreoretinal surgery. Ophthalmology (2005) 0.92
Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome. Arch Ophthalmol (2009) 0.92
High-speed optical coherence tomography as a reliable adjuvant tool to grade ocular anterior chamber inflammation. Retina (2014) 0.90
Clinical management of proliferative vitreoretinopathy: an update. Retina (2015) 0.90
The competency of pars plana vitrectomy incisions: a comparative histologic and spectrophotometric analysis. Am J Ophthalmol (2008) 0.89